Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-29

Ok so here is the deal.

I understand many pharma companies are trying to cash in on treatment for COVID-19.

Mesoblast, has a massive head start on competitors in treating disease with Mesenchymal Stem Cells.
When I say head start, I mean they have at least 5-10 years on most competitors and heavily scrutinized clinical trial data on their remestemcel-L/temcell product.

They are a global leader and so when Professor Silviu Itescu says they are in active discussions with Governments for use of remestemcel-L an advanced and commercial product then I think it’s time the market sat up and finally listened.

This isn’t a cure however studies show the product has the potential and described in the announcment to treat this life- threatening virus and stabilise high-risk patients to a pathway of full recovery.

This is for real and yes the announcement should have come a little earlier as I suggested a few days ago.

But it’s here and Mesoblast is in a great position to help the globe.